Caprock Group, Inc. Puma Biotechnology, Inc. Transaction History
Caprock Group, Inc.
- $3.21 Billion
- Q1 2025
A detailed history of Caprock Group, Inc. transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Caprock Group, Inc. holds 13,817 shares of PBYI stock, worth $44,767. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,817Holding current value
$44,767% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PBYI
# of Institutions
116Shares Held
31MCall Options Held
32.7KPut Options Held
200-
Acorn Capital Advisors, LLC New York, NY3.94MShares$12.8 Million8.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.67MShares$11.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$11.6 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$6.51 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.83MShares$5.93 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $148M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...